12 results on '"Biragyn, Arya"'
Search Results
2. Cancer co-opts differentiation of B-cell precursors into macrophage-like cells.
- Author
-
Chen, Chen, Park, Bongsoo, Ragonnaud, Emeline, Bodogai, Monica, Wang, Xin, Zong, Le, Lee, Jung-Min, Beerman, Isabel, and Biragyn, Arya
- Subjects
REGULATORY T cells ,T cells ,BONE marrow ,INTERLEUKIN-21 ,TUMOR microenvironment ,CANCER invasiveness ,B cells - Abstract
We have recently reported that some cancers induce accumulation of bone marrow (BM) B-cell precursors in the spleen to convert them into metastasis-promoting, immunosuppressive B cells. Here, using various murine tumor models and samples from humans with breast and ovarian cancers, we provide evidence that cancers also co-opt differentiation of these B-cell precursors to generate macrophage-like cells (termed B-MF). We link the transdifferentiation to a small subset of CSF1R
+ Pax5Low cells within BM pre-B and immature B cells responding to cancer-secreted M-CSF with downregulation of the transcription factor Pax5 via CSF1R signaling. Although the primary source of tumor-associated macrophages is monocytes, B-MFs are phenotypically and functionally distinguishable. Compared to monocyte-derived macrophages, B-MFs more efficiently phagocytize apoptotic cells, suppress proliferation of T cells and induce FoxP3+ regulatory T cells. In mouse tumor models, B-MFs promote shrinkage of the tumor-infiltrating IFNγ+ CD4 T cell pool and increase cancer progression and metastasis, suggesting that this cancer-induced transdifferentiation pathway is functionally relevant and hence could serve as an immunotherapeutic target. The tumour microenvironment has been shown to change the phenotypes and functionality of immune cells to enable tumour propagation. Here authors show that cancers can derail B cell development to give rise to macrophage-like cells, contributing to cancer progression and metastasis via disabling local T cell response. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
3. Therapeutic B-cell depletion reverses progression of Alzheimer's disease.
- Author
-
Kim, Ki, Wang, Xin, Ragonnaud, Emeline, Bodogai, Monica, Illouz, Tomer, DeLuca, Marisa, McDevitt, Ross A., Gusev, Fedor, Okun, Eitan, Rogaev, Evgeny, and Biragyn, Arya
- Subjects
ALZHEIMER'S disease ,AMYLOID plaque ,TRANSGENE expression ,B cells ,TRANSGENIC animals - Abstract
The function of B cells in Alzheimer's disease (AD) is not fully understood. While immunoglobulins that target amyloid beta (Aβ) may interfere with plaque formation and hence progression of the disease, B cells may contribute beyond merely producing immunoglobulins. Here we show that AD is associated with accumulation of activated B cells in circulation, and with infiltration of B cells into the brain parenchyma, resulting in immunoglobulin deposits around Aβ plaques. Using three different murine transgenic models, we provide counterintuitive evidence that the AD progression requires B cells. Despite expression of the AD-fostering transgenes, the loss of B cells alone is sufficient to reduce Aβ plaque burden and disease-associated microglia. It reverses behavioral and memory deficits and restores TGFβ
+ microglia, respectively. Moreover, therapeutic depletion of B cells at the onset of the disease retards AD progression in mice, suggesting that targeting B cells may also benefit AD patients. Alzheimer's disease is characterized by progressive dementia and amyloid beta plaque deposition. Here the authors show in three relevant transgenic animal models that accumulation of activated B cells is central to AD pathology and depletion of B cells interferes with both histological and behavioural manifestations of the disease. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
4. Potential importance of B cells in aging and aging-associated neurodegenerative diseases.
- Author
-
Biragyn, Arya, Aliseychik, Maria, and Rogaev, Evgeny
- Subjects
- *
B cells , *CELLULAR aging , *NEURODEGENERATION , *RHEUMATOID arthritis , *MULTIPLE sclerosis , *IMMUNOSUPPRESSION - Abstract
Our understanding of B cells as merely antibody producers is slowly changing. Alone or in concert with antibody, they control outcomes of seemingly different diseases such as cancer, rheumatoid arthritis, diabetes, and multiple sclerosis. While their role in activation of effector immune cells is beneficial in cancer but bad in autoimmune diseases, their immunosuppressive and regulatory subsets (Bregs) inhibit autoimmune and anticancer responses. These pathogenic and suppressive functions are not static and appear to be regulated by the nature and strength of inflammation. Although aging increases inflammation and changes the composition and function of B cells, surprisingly, little is known whether the change affects aging-associated neurodegenerative disease, such as Alzheimer's disease (AD). Here, by analyzing B cells in cancer and autoimmune and neuroinflammatory diseases, we elucidate their potential importance in AD and other aging-associated neuroinflammatory diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. A new paradigm for an old story: the role of regulatory B cells in cancer.
- Author
-
Biragyn, Arya and Lee-Chang, Catalina
- Subjects
B cells ,CANCER ,CANCER immunology ,IMMUNOGLOBULINS ,CELLULAR immunity ,IMMUNE response - Abstract
The article discusses the role of B cells in cancer. It mentions that B cells have pathogenic antitumor properties that participate in the carcinogenesis of transplanted tumors. It notes that such cell can produce immunoglobulins for suppression of cellular immune responses. It emphasizes that B cells are also important in mediation of cancer escape.
- Published
- 2012
- Full Text
- View/download PDF
6. Correction to: Potential importance of B cells in aging and aging-associated neurodegenerative diseases.
- Author
-
Biragyn, Arya, Aliseychik, Maria, and Rogaev, Evgeny
- Subjects
- *
B cells , *NEURODEGENERATION - Abstract
The original version of this article unfortunately contained mistakes. Two references were given incorrectly (under number 40 and 41). [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Aging Converts Innate B1a Cells into Potent CD8+ T Cell Inducers.
- Author
-
Lee-Chang, Catalina, Bodogai, Monica, Moritoh, Kanako, Xin Chen, Wersto, Robert, Sen, Ranjan, Young, Howard A., Croft, Michael, Ferrucci, Luigi, and Biragyn, Arya
- Subjects
- *
CELLULAR aging , *CD8 antigen , *B cells , *MAJOR histocompatibility complex , *MACROPHAGE activation , *T cells , *DISEASES , *PHYSIOLOGY - Abstract
B cell dysregulation in aging is thought to mostly occur in conventional B2 cells without affecting innate B1 cells. Elderly humans and mice also accumulate 4-1BBL+ MHC class-IHi CD86Hi B cells of unknown origin. In this article, we report that these cells, termed 4BL cells, are activated murine and possibly human B1a cells. The activation is mediated by aging human monocytes and murine peritoneal macrophages. They induce expression and activation of 4-1BBL and IFN-γR1 on B1a cells to subsequently upregulate membrane TNF-α and CD86. As a result, activated B1a/4BL cells induce expression of granzyme B in CD8+ T cells by targeting TNFR2 via membrane TNF-α and providing costimulation with CD86. Thus, for the first time, to our knowledge, these results indicate that aging affects the function of B1a cells. Upon aging, these cells lose their tumor-supporting activity and become inducers of potentially antitumor and autoimmune CD8+ T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
8. Accumulation of 4-1BBL+ B cells in the elderly induces the generation of granzyme-B+ CD8+ T cells with potential antitumor activity.
- Author
-
Lee-Chang, Catalina, Bodogai, Monica, Moritoh, Kanako, Olkhanud, Purevdorj B., Chan, Andrew C., Croft, Michael, Mattison, Julie A., Holst, Peter Johannes, Gress, Ronald E., Ferrucci, Luigi, Hakim, Fran, and Biragyn, Arya
- Subjects
- *
B cells , *GRANZYMES , *T cells , *ANTINEOPLASTIC agents , *IMMUNE reconstitution inflammatory syndrome , *CANCER chemotherapy , *PROGENITOR cells , *CELL transplantation - Abstract
Although the accumulation of highly-differentiated and granzyme B (GrB)-expressing CD8+CD28- T cells has been associated with aging, the mechanism for their enrichment and contribution to immune function remains poorly understood. Here we report a novel B-cell subset expressing 4-1BBL, which increases with age in humans, rhesus macaques, and mice, and with immune reconstitution after chemotherapy and autologous progenitor cell transplantation. These cells (termed 4BL cells) induce GrB+CD8+ T cells by presenting endogenous antigens and using the 4-1BBL/4-1BB axis. We found that the 4BL cells increase antitumor responses in old mice, which may explain in part the paradox of retarded tumor growth in the elderly. 4BL cell accumulation and its capacity to evoke the generation of GrB+CD8+ T cells can be eliminated by inducing reconstitution of B cells in old mice, suggesting that the age-associated skewed cellular immune responses are reversible. We propose that 4BL cells and the 4-1 BBL signaling pathway are useful targets for improved effectiveness of natural antitumor defenses and therapeutic immune manipulations in the elderly. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Inhibition of Breast Cancer Metastasis by Resveratrol-Mediated Inactivation of Tumor-Evoked Regulatory B Cells.
- Author
-
Lee-Chang, Catalina, Bodogai, Monica, Martin-Montalvo, Alejandro, Wejksza, Katarzyna, Sanghvi, Mitesh, Moaddel, Ruin, de Cabo, Rafael, and Biragyn, Arya
- Subjects
- *
BREAST cancer , *METASTASIS , *RESVERATROL , *B cells , *TRANSFORMING growth factors , *T cells , *LABORATORY mice , *THERAPEUTICS - Abstract
We reported previously that tumor-evoked regulatory B cells (tBregs) play an essential role in breast cancer lung metastasis by inducing TGF-β-dependent conversion of metastasis-promoting Foxp3+ regulatory T cells (Tregs). In this article, we show that resveratrol (RSV), a plant-derived polyphenol, at low and noncytotoxic doses for immune cells, can efficiently inhibit lung metastasis in mice. The mechanism of this process is that RSV inactivates Stat3, preventing the generation and function of tBregs, including expression of TGF-β. As a result, it frees antitumor effector immune responses by disabling tBreg-induced conversion of Foxp3+ Tregs. We propose that low doses of RSV may also benefit humans by controlling cancer escape-promoting tBregs/Tregs without nonspecific inactivation of effector immune cells. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L.
- Author
-
Bodogai, Monica, Chang, Catalina Lee, Wejksza, Katarzyna, Jinping Lai, Merino, Maria, Wersto, Robert P., Gress, Ronald E., Chan, Andrew C., Hesdorffer, Charles, and Biragyn, Arya
- Subjects
- *
B cells , *TUMORS , *CANCER cells , *IMMUNITY , *BREAST cancer research - Abstract
The possible therapeutic benefits of B-cell depletion in combating tumoral immune escape have been debated. In support of this concept, metastasis of highly aggressive 4T1 breast cancer cells in mice can be abrogated by inactivation of tumor-evoked regulatoryB cells (tBreg). Here, we report the unexpected finding that B-cell depletion by CD20 antibody will greatly enhance cancer progression and metastasis. Both murine and human tBregs express low levels of CD20 and, as such, anti-CD20 mostly enriches for these cells. In the 4T1 model of murine breast cancer, this effect of enriching for tBregs suggests that B-cell depletion by anti-CD20 may not be beneficial at all in some cancers. In contrast, we show that in vivo--targeted stimulation of B cells with CXCL13-coupled CpG oligonucleotides (CpG-ODN) can block cancer metastasis by inhibitingCD20Low tBregs.Mechanistic investigations suggested that CpG-ODN upregulates low surface levels of 4-1BBL on tBregs to elicit granzyme B-expressing cytolytic CD8+ T cells, offering some explanative power for the effect. These findings underscore the immunotherapeutic importance of tBreg inactivation as a strategy to enhance cancer therapy by targeting both the regulatory and activating arms of the immune system in vivo. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
11. Cancer-Produced Metabolites of 5-Lipoxygenase Induce Tumor-Evoked Regulatory B Cells via Peroxisome Proliferator-Activated Receptor α.
- Author
-
Wejksza, Katarzyna, Lee-Chang, Catalina, Bodogai, Monica, Bonzo, Jessica, Gonzalez, Frank J., Lehrmann, Elin, Becker, Kevin, and Biragyn, Arya
- Subjects
- *
BREAST cancer research , *LIPOXYGENASES , *METABOLITE synthesis , *PEROXISOME proliferator-activated receptors , *B cells , *TARGETED drug delivery , *LEUKOTRIENES , *IMMUNOSUPPRESSION - Abstract
Breast cancer cells facilitate distant metastasis through the induction of immunosuppressive regulatory B cells, designated tBregs. We report in this study that, to do this, breast cancer cells produce metabolites of the 5-lipoxygenase pathway such as leukotriene B4 to activate the peroxisome proliferator-activated receptor α (PPARα) in B cells. Inactivation of leukotriene B4 signaling or genetic deficiency of PPARα in B cells blocks the generation of tBregs and thereby abrogates lung metastasis in mice with established breast cancer. Thus, in addition to eliciting fatty acid oxidation and metabolic signals, PPARα initiates programs required for differentiation of tBregs. We propose that PPARα in B cells and/or tumor 5-lipoxygenase pathways represents new targets for pharmacological control of tBreg-mediated cancer escape. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
12. DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid β-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease
- Author
-
Olkhanud, Purevdorj B., Mughal, Mohammed, Ayukawa, Koichi, Malchinkhuu, Enkhzol, Bodogai, Monica, Feldman, Neil, Rothman, Sarah, Lee, Jong-Hwan, Chigurupati, Srinivasulu, Okun, Eitan, Nagashima, Kunio, Mattson, Mark P., and Biragyn, Arya
- Subjects
- *
ALZHEIMER'S disease vaccines , *DISEASE progression , *IMMUNIZATION , *GENE expression , *B cells , *DNA vaccines , *EPITOPES , *TARGETED drug delivery , *LABORATORY mice - Abstract
Abstract: Alzheimer''s disease (AD) is an incurable and progressive neurodegenerative senile disorder associated with the brain accumulation of Aβ plaques. Although vaccines that reduce Aβ plaques can control AD, the rationale for their use at the onset of the disease remains debatable. Old humans and mice usually respond poorly to vaccines due to presumably age-related immunological impairments. Here, we report that by modifying vaccines, the poor responsiveness of old mice can be reversed. Unlike the Aβ peptide vaccine, DNA immunizations with the amino-terminal Aβ(1–11) fragment exposed on the surface of HBsAg particles elicit high levels of anti-Aβ antibody both in young and old mice. Importantly, in AD model 3xTgAD mice, the vaccine reduced Aβ plaques, ameliorated cognitive impairments and, surprisingly, significantly increased life span. Hence, we propose that vaccines targeting Aβ(1–11) can efficiently combat AD-induced pathological alterations and provide survival benefit in patients with AD. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.